Elaine Sullivan discusses Asset POLB 002 & Respiratory Viruses

Poolbeg’s Scientific Advisory Board member, Dr Elaine Sullivan discusses why respiratory viruses are such a global threat & why she is so excited about our recent asset acquisition, POLB 002, an RNA-based immunotherapy for respiratory virus infections.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

More articles like this

Poolbeg Pharma: GMP manufacturing contract signed

Update on POLB 001 Clinical Development GMP manufacturing contract signed ensuring ample supply of POLB 001 for clinical development and for use in investigating further potential disease indications Poolbeg Pharma announced an update on its lead asset, POLB 001,

Poolbeg to engage with key international stakeholders at Congress

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, is participating in the European Melioidosis Congress (EMC) 2022, due to take place 16 May 2022 – 18 May 2022 in Graz,

Key POLB 002 European patent granted

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Investors to buy €1.9m shares in Poolbeg Pharma

Infectious disease company Poolbeg Pharma has said a number of new investors have expressed interest in acquiring up to £1.6 million (€1.9m) of its shares which are currently locked up and held in trust by Croft Nominees. The investors have

Poolbeg Pharma granted an important patent

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announced on Thursday an update on the strengthening of its intellectual property (IP) for its asset POLB 002, a first-in-class,

Poolbeg Pharma absolutely delighted with new investor interest

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announced this week that a number of new investors have expressed interest in acquiring up to £1.6m of Poolbeg

CEO Jeremy Skillington on OTCQB listing

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma POLB 001 Clinical Development 

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma signs deal with AI company on influenza data

Infectious disease specialist Poolbeg Pharma has signed a deal with artificial intelligence company CytoReason to provide analysis of data from human challenge studies on influenza. The project, which is due to commence immediately,could yield new and better treatments for influenza.

Poolbeg Pharma results to 31 December 2021 

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

No more posts to show